White matter hyperintensities, shown above, are the tell-tale sign of vascular depression. They represent small ischemic injuries and may be described as normal signs of aging.
It resists standard antidepressants, and a new review finds more effective options
STUDY: Flôr-Rodrigues B et al, International Psychogeriatrics 2026, doi:10.1016/j.inpsyc.2026.100249
STUDY TYPE: Systematic review of randomized controlled trials
FUNDING: Academic and hospital sources (Lausanne University Hospital, University of Lausanne); not industry-funded
Background
Vascular depression is a common cause of antidepressant non-response, particularly in late-life depression where the rates rise up towards 100%.
Among patients with depression, the rate of vascular contributions rises with age (from Difficult to Treat Depression)
Unlike post-stroke depression, this subtype doesn’t respond well to antidepressants, which are around 35% less effective when these microvascular injuries are scattered throughout the brain.
Here are the cardinal signs:
- Vascular disease
- Older age
- Apathy
- Motoric and cognitive slowing
- Poor insight and low executive dysfunction
- White matter hyperintensities on brain imaging
Another sign: Your patient responded to a specific antidepressant at age 45, but not at age 72.
No treatment guidelines exist, so this review gathered every randomized trial testing a treatment in this population.
The Study
- 8 randomized trials (2001-2025; 4 China, 2 Argentina, 1 each US and Italy), 84-136 patients each, mean ages 64-72, follow-up of 10 days to 10 months.
- Four trials added tandospirone (a serotonin 1A partial agonist) to a standard antidepressant; two added nimodipine; two tested brain stimulation (magnetic and direct current) against sham.
Results
Tandospirone sped recovery in three open-label or single-blind trials, but response rates matched antidepressant alone by week 8. The single double-blind trial found no advantage with tandospirone, but it was limited as it did not check mood over first four weeks.
Nimodipine, the anti-hypertensive and calcium channel blocker, improved remission as augmentation to fluoxetine. It roughly doubled remission (54% versus 27%; NNT 4) and lowered six-month relapse (3.7% versus 35.7%; NNT 3).
TMS and direct current stimulation (tDCS) are also effective. Twice-daily tDCS brought 68% to response versus none on sham, and the higher-dose TMS brought 39% to response versus 7%. These neuromodulation techniques also improved cognition independent of mood.
Side Effects
Adverse events were mild and transient across all eight trials, with no serious events attributed to treatment. Hypotension occurred more often with nimodipine, and twice-daily direct current stimulation caused mild scalp redness in over half the patients.
Limitations
Small trials, most of low or very low certainty. Half came from one Chinese center. The tandospirone finding rests mainly on unblinded trials.
More Options
I’ll step outside the entry requirements for this analysis and highlight a few options worth considering:
- Lithium has a promising neuroprotective mechanism, reduces atherosclerosis, and favorable results in geriatric depression, but no trials in vascular depression.
- The phosphodiesterase inhibitors pentoxifylline (400 mg bid-tid) and cilostazol (100 mg/day) have positive trials in depression and a relevant mechanism to vascular disease (anti-inflammatory, neuroprotective, and improving cerebral blood flow). Evidence for pentoxifylline is more extensive (four RCTs plus preclinical work), while cilostazol rests on a single human pilot trial.
- Ginkgo has 4 large and 10 small randomized trials in depression with cardiovascular disease (86% are positive, 120-240 mg bid). I suspect it was missed by this analysis because it is not a medication, the studies are in Chinese, or “depression with cardiovascular disease” is not the same as “vascular depression.” Ginkgo also has large and 2 small randomized trials in post-stroke depression (91% are positive), where it improved mood and cognition. I review it in the upcoming Carlat Fact Book on Complimentary and Alternative Medicine in Psychiatry and have lab-tested products here.
- Citicoline is neuroprotective and improved mood and cognition in various populations with brain injury, including post-stroke, vascular disease, cocaine use, and age-related cognitive decline.
- Psychotherapy can benefit from techniques to aid executive functioning, such as dexterity games, cognitive training, and memory aids.
Practice Implications
- Mood disorders cause vascular disease, and vice-versa, so these two often overlap.
- When you see vascular depression, address vascular disease (make sure they are seeing a PCP), get input from the family (they’ll know more about dysfunction), and consider moving outside antidepressants.
- Learn more about how to manage it in Difficult to Treat Depression.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report
